Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers

다국어 초록 (Multilingual Abstract)

Oncogenic gain-of-function mutations are clinical biomarkers for most targeted therapies, as well as represent direct targets for drug treatment. Although loss-of-function mutations involving the tumor suppressor gene, STK11 (LKB1) are important in lung cancer progression, STK11 is not the direct target for anticancer agents. We attempted to identify cancer transcriptome signatures associated with STK11 loss-offunction mutations. Several new sensitive and specific gene expression markers (ENO3, TTC39C, LGALS3, and MAML2) were identified using two orthogonal measures, i.e., fold change and odds ratio analyses of transcriptome data from cell lines and tissue samples. Among the markers identified, the ENO3 gene over-expression was found to be the direct consequence of STK11 loss-of-function. Furthermore, the knockdown of ENO3 expression exhibited selective anticancer effect in STK11 mutant cells compared with STK11 wild type (or recovered) cells. These findings suggest that ENO3 -based targeted therapy might be promising for patients with lung cancer harboring STK11 mutations.

참고문헌 (Reference)

1 Liu, K. J., "The role of enolase in tissue invasion and metastasis of pathogens and tumor cells" 3 : 45-48, 2007

2 Cancer Genome Atlas Research Network, "The Cancer Genome Atlas Pan-cancer analysis project" 45 : 1113-1120, 2013

3 Barretina, J., "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" 483 : 603-607, 2012

4 Clough, E., "Statistical Genomics" Humana Press 93-110, 2016

5 Muller, F. L., "Passenger deletions generate therapeutic vulnerabilities in cancer" 488 : 337-342, 2012

6 Carretero, J., "Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene" 23 : 4037-4040, 2004

7 Peshavaria, M., "Molecular structure of the human muscle-specific enolase gene(ENO3)" 275 : 427-433, 1991

8 Planchard, D., "Metastatic nonsmall cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" 29 (29): iv192-iv237, 2018

9 Novello, S., "Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" 27 (27): v1-v27, 2016

10 Song, M., "Loss-of-function screens of druggable targetome against cancer stem-like cells" 31 : 625-635, 2017

11 Facchinetti, F., "LKB1/STK11 mutations in non-small cell lung cancer patients : descriptive analysis and prognostic value" 112 : 62-68, 2017

12 Gao, Y., "LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling" 107 : 18892-18897, 2010

13 He, N., "Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D" 13 : 2463-2473, 2014

14 Lung, J., "In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically" 11 : 3281-3290, 2017

15 Ali, H., "Identification of suitable reference genes for gene expression studies using quantitative polymerase chain reaction in lung cancer in vitro" 11 : 3767-3773, 2015

16 Gill, R. K., "Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer" 30 : 3784-3791, 2011

17 Ho, J. A., "Diagnostic detection of human lung cancer-associated antigen using a gold nanoparticle-based electrochemical immunosensor" 82 : 5944-5950, 2010

18 Liu, D. W., "Choice of endogenous control for gene expression in nonsmall cell lung cancer" 26 : 1002-1008, 2005

19 Kim, N., "Cardiac glycosides display selective efficacy for STK11 mutant lung cancer" 6 : 29721-, 2016

20 Isgrò, M. A., "Advances in Cancer Biomarkers" Springer 125-143, 2015

21 Chen, L., "A sensitive NanoStringbased assay to score STK11(LKB1)pathway disruption in lung adenocarcinoma" 11 : 838-849, 2016